Plant Bioactive Compounds for Pancreatic Cancer Prevention and Treatment


Christopher J. Scarlett and Quan V. Vuong (Editors)
University of Newcastle, Australia

Series: Cancer Etiology, Diagnosis and Treatments
BISAC: MED062000

With the rapid advancements in medical research, diagnostic technology and increased public health initiative and awareness, overall cancer death rates in western societies are declining each year with the number of deaths from major cancers such as breast, colorectal and lung following this trend. However, the survival rate for those with pancreatic cancer has been at a standstill for over four decades and there are concerns that pancreatic cancer may become the second deadliest cancer in the US by the year 2030. The diagnosis of pancreatic cancer has dire consequences as it presents late in its course and is rapidly progressive.

This is clearly one of the most devastating of human cancers, and as there are very few treatment options for those with the disease, new approaches and novel therapeutic strategies are urgently required. For thousands of years, plants have been used as traditional indigenous remedies for a variety of ailments in many parts of the world. It is thought that approximately 80% of the rural population worldwide still relies on plants as medicines. Plants have assumed the greatest prominence as a source of medicinal compounds with thousands of species associated with the treatment of cancers or conditions with cancer-like symptoms.

Scientific evaluation of a range of traditional medicines has led to the development of highly effective cancer therapeutic agents, and it is estimated that approximately 50% of all pharmaceuticals currently available for administration are still derived from natural origins. With this in mind, within the plant kingdom there remains great potential for the development of novel therapeutic agents with significant efficacy against pancreatic cancer. With our increasing understanding of the molecular pathology of pancreatic cancer and the rapid advancement of DNA sequencing technology to understand the structure of the genome and infer biology, pancreatic cancer is one of the most appropriate diseases to test multiple novel plant derived therapeutics in a molecular phenotype driven personalized approach.
(Imprint: Nova)


Table of Contents

Table of Contents


Chapter 1 – Pancreatic Cancer: Challenges for Therapeutic Development (pp. 1-28)
Nigel B. Jamieson, Sean M. Grimmond, Andrew V. Biankin, David K. Chang and the Australian Pancreatic Cancer Genome Initiative (Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow, G61 1BD, United Kingdom and others)

Chapter 2 – History and Development of Plant-Derived Anti-Cancer Agents (pp. 29-44)
Emily K. Colvin (Colvin, Bill Walsh Translational Cancer Research Laboratory, Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, St Leonards, NSW, 2065, Australia)

Chapter 3 – Traditional Use of Plants As Folk Medicine (pp. 45-58)
Andrew Pengelly PhD, FNHAA, RH-AHG (Herbal Medicine Program, Maryland University of Integrative Health, 7750 Montpelier Road, Laurel, MD, USA)

Chapter 4 – Bioactive Plants and Health Benefits (pp. 59-80)
Renée A. Street and Lyndy J. McGaw (HIV Prevention Research Unit, South African Medical Research Council, 123 Jan Hofmeyr Road, Westville, Durban, and Phytomedicine Programme, Department of Paraclinical Sciences, University of Pretoria, Private Bag X04, Onderstepoort 0110, Pretoria, South Africa)

Chapter 5 – Bioactive Composition of Plants and Plant Foods (pp. 81-116)
Nenad Naumovski, PhD (Discipline of Nutrition and Dietetics, Faculty of Health, University of Canberra, Canberra, ACT, Australia)

Chapter 6 – Extraction and Isolation of Plant Bioactives (pp. 117-144)
Tuyen C. Kha and Minh H. Nguyen (School of Environmental and Life Sciences, University of Newcastle, Ourimbah, NSW, Australia and others)

Chapter 7 – Pancreatic Cancer Drugs: Case Studies in Synthesis and Production (pp. 145-194)
Christopher J. Scarlett, Quan V. Vuong, Adam McCluskey and Michael C. Bowyer (School of Environmental & Life Sciences, University of Newcastle, Australia)

Chapter 8 – Selected Australian Flora As Potential Sources of Anti-Cancer Agents (pp. 195-218)
Quan V. Vuong and Christopher J. Scarlett (Pancreatic Cancer Research, Nutrition, Food & Health Research Group, School of Environmental & Life Sciences, University of Newcastle, 10 Chittaway Rd, Ourimbah, NSW 2258)

Chapter 9 – Vietnamese Medicinal Plants As Potential Anti-Cancer Agents (pp. 219-248)
Phuong Thien Thuong, Nguyen Minh Khoi, Christopher J. Scarlett and Fumiaki Ito (Vietnam National Institute of Medicinal Materials, 3B Quang Trung, Hoan Kiem, Hanoi, Vietnam and others)

Chapter 10 – Plants in the Subcontinent As Potential Anti-Cancer Agents (pp. 249-268)
Bharat Z. Dholakiya and Jigarkumar R. Patel (Applied Chemistry Department, S. V. National Institute of Technology (SVNIT), Surat 395 007, Gujarat-India)

Chapter 11 – Plants in Africa As Potential Anti-Cancer Agents (pp. 269-300)
M. S. Abubakar (Professor of Pharmacognosy & Head of Department, Pharmacognosy and Drug Development, Faculty of Pharmaceutical Sciences, Ahmadu Bello University, Zaria, Nigeria)



Publish with Nova Science Publishers

We publish over 800 titles annually by leading researchers from around the world. Submit a Book Proposal Now!